{"entity":{"id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","aka":[],"tldr":"Once two drugs of a kind exist, a third should have to prove itself against the best of them, not against an outdated comparison, so patients and payers learn which is actually better.","summary":"Regulators (or payers, through reimbursement rules) require that registration trials for the third and later entrants in an established mechanistic class use the best available in-class agent as the active comparator, or at minimum include a randomised head-to-head arm. Exceptions apply where the new agent addresses a population the incumbents do not. This makes me-too development more expensive and more informative at once: it either yields comparative evidence patients need or diverts capital to novel mechanisms.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)","url":"https://doi.org/10.1038/d41573-022-00030-4"}],"tags":[],"related":["idea-fund-benefit-indexed-exclusivity"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","nivolumab","sacituzumab-govitecan","datopotamab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":["standard-of-care"],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-trial-design"],"keyPapers":["paper-upadhaya-nat-rev-drug-discov"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A head-to-head requirement reduces late-in-class registration filings by at least a quarter within five years and produces comparative effectiveness evidence for the majority of remaining in-class approvals, where today almost none exists.","rationale":"The EU and payers such as Germany's G-BA already prefer active comparators; the WHO and IQWiG have argued that placebo- or obsolete-comparator trials waste patients. Comparative trials among PD-1 antibodies and among TROP2 ADCs are essentially absent despite dozens of products.","test":"Implement through a payer coalition's reimbursement criteria (faster than legislation) and count filings and comparator choices in oncology over three years against a pre-period.","maturity":"speculative","actor":"regulator","cost":"small","horizonYears":5},"route":"/ideas/idea-fund-head-to-head-mandate/","neighbours":{"idea":[{"id":"idea-fund-compulsory-combination-access","kind":"idea","name":"A legal right to obtain marketed cancer drugs at cost for combination trials","route":"/ideas/idea-fund-compulsory-combination-access/"},{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/"},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"standard-of-care","kind":"term","name":"Standard of care","route":"/terms/standard-of-care/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/"}]}}